Fig 1: Drug susceptibility analysis of SLC30A1-10 genes. A positive correlation between gene expression and drug indicates that the gene has an antagonistic effect on the drug.
Fig 2: The top-20 correlated genes and GSEA analysis of SLC30A1/10 in cervical carcinoma. (A, C) The heatmap showing the top 20 genes positively or negatively correlated with SLC30A1 or SLC30A10. (B, D) GSEA analysis of SLC30A1 or SLC30A10.
Fig 3: ROC curves and immunohistochemistry results of SLC30A1 and SLC30A10 in cervical carcinoma. (A) SLC30A1, AUC=0.8878 (95%CI: 0.8309 - 0.9448), p < 0.0001; SLC30A10, AUC=0.8314 (95% CI: 0.7939 - 0.8689), p <0.0001. (B) SLC30A1 and SLC30A10 proteins were higher in cervical carcinoma, compared to tumor-adjacent tissues.
Fig 4: The cancer related pathways (A), correlation heat map (B), survival analysis (C) of SLC30A1-10 genes in cervical carcinoma.
Fig 5: Genetic mutations in SLC30A1-10 genes and their association neighbor genes network (STRING, GeneMANIA and cBioPortal). (A) The network contains 10 nodes. (B) Protein-protein interaction network of SLC30A1-10 genes. (C) Summary of alterations in differently expressed SLC30A1-10 genes in cervical carcinoma.
Supplier Page from Abcam for Anti-ZnT1 antibody